Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Serum metabolism marker for diagnosing benign and malignant pulmonary nodules and application of the metabolic marker

A technology of metabolic markers and metabolites, which is applied in the diagnosis of benign and malignant pulmonary nodules, serum metabolic markers and its screening, can solve the problems of single sample source, metabolites with low disease specificity, and limited clinical significance. Achieve the effect of reducing trauma and radiation risk

Pending Publication Date: 2022-01-21
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these studies basically use metabolite information from public databases, and the metabolite disease specificity obtained by screening is not strong, and most of the studies are from a single sample source, and the actual clinical significance is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serum metabolism marker for diagnosing benign and malignant pulmonary nodules and application of the metabolic marker
  • Serum metabolism marker for diagnosing benign and malignant pulmonary nodules and application of the metabolic marker
  • Serum metabolism marker for diagnosing benign and malignant pulmonary nodules and application of the metabolic marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] This embodiment provides a screening method for serum metabolic markers, comprising the following steps:

[0035] S1, collecting samples

[0036] In this study, after obtaining the consent of the patients, peripheral venous blood was collected from 140 patients with benign pulmonary nodules (benign pulmonary nodules group) and 143 patients with malignant pulmonary nodules (malignant pulmonary nodules group) in Shanghai Chest Hospital. Serum samples. All patients with pulmonary malignant nodules had no history of other malignant tumors, other major systemic diseases, and no chronic medical history of long-term medication. The time of blood collection was in the morning on an empty stomach. All serum samples were centrifuged and stored in a -80°C refrigerator. During the study, serum samples were taken out and thawed for subsequent analysis.

[0037] S2, Extensive targeted metabolomics analysis of serum

[0038] (1) Sample pretreatment

[0039] Take out the sample co...

Embodiment 2

[0076] The research objects of this example included 70 serum samples of patients with benign pulmonary nodules and 71 serum samples of malignant pulmonary nodules from 2 independent medical centers. All patients with benign and malignant pulmonary nodules had no other history of malignant tumors, other major systemic diseases, and no chronic medical history of long-term medication. The time of blood collection was in the morning on an empty stomach. All serum samples were centrifuged and stored in a -80°C refrigerator. During the study, serum samples were taken out and thawed for subsequent analysis.

[0077] The detection conditions and data analysis methods of this example are the same as those of Example 1, and the differential metabolites detected and analyzed are the following 12 kinds: 4-hydroxy-L-proline, hyodeoxycholic acid, xanthine, 2-hydroxy- 6-aminopurine, 5,6-dihydrothymine, isobutyrylcarnitine, guanine, glutamic acid, asparagine, formononetin, alanine, kynuric ...

Embodiment 3

[0095] This embodiment provides a detection kit, comprising:

[0096] (1) Standards for metabolic markers: hydroxy-L-proline, hyodeoxycholic acid, xanthine, 2-hydroxy-6-aminopurine, 5,6-dihydrothymine, isobutyrylcarnitine, Guanine, glutamic acid, asparagine, formononetin, alanine, kynuuric acid, individually packaged or mixed packaged.

[0097] (2) Solvent:

[0098] Pure methanol and 50% acetonitrile in water for sample extraction.

[0099] 50% acetonitrile in water can be used as a solvent to dissolve the standards.

[0100] (3) Internal standard: L-phenylalanine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a metabolic marker for diagnosing benign and malignant pulmonary nodules and application of the metabolic marker. The metabolic marker is selected from one or combination of 4-hydroxy-L-proline, hyodeoxycholic acid, xanthine, 2-hydroxy-6-aminopurine, 5, 6-dihydrothymine, isobutyryl carnitine, guanine, glutamic acid, asparagine, formononetin, alanine and kynuric acid. The 12 metabolic markers provided by the invention can accurately diagnose and distinguish lung benign and malignant nodules, have high sensitivity and strong specificity, can well replace the existing tissue biopsy and imaging diagnosis mode, reduce trauma and radiation risks, and have clinical use and popularization values.

Description

technical field [0001] The invention relates to the technical field of detection and diagnosis, in particular to a serum metabolic marker for the diagnosis of benign and malignant pulmonary nodules, a screening method and application thereof. Background technique [0002] Lung cancer is the disease with the highest morbidity and mortality in China. In the past three decades, the mortality rate of lung cancer has increased by about 5 times. The main reason is that 75% of cancer patients are diagnosed in the middle and late stages. The detection rate of early lung cancer is less than 25%, but the 5-year survival rate of early lung cancer is over 90%, but because its early features are not obvious, the best way to find lung cancer is to regularly screen for lung nodules. [0003] Pulmonary nodule is an imaging term. When there is a round or oval <3cm gray or white shadow in a place that should not be occluded on the lung image, we call it a nodule. Nodules can be granulomas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/50
CPCG01N33/57423G01N33/57488G01N33/50
Inventor 娄加陶王琳范江王兴
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com